Thursday, Apr 21, 1994

Genentech Files Suit Against Centocor

South San Francisco, Calif. -- April 21, 1994 --

Genentech, Inc., (NYSE: GNE) announced today it has filed a patent infringement complaint in the U.S. District Court for Northern California against Centocor, Inc. for infringing its pioneering "Cabilly Patent" which covers antibody technology related to chimeric immunoglobulin compositions, expression vectors and methods.

The patent suit encompasses all of Centocor's infringing activities, including supplying CentoRx, IIb/IIIa inhibitor being studied by Eli Lilly & Co. The Centocor product has been exclusively licensed to Eli Lilly & Co. The suit asserts that Centocor has made, used and sold immunoglobulin preparations which fall within the scope of the claims of U.S. Patent No. 4,816,567. Twelve licenses have been taken under the Cabilly patent.

Genentech, Inc. is a leading international biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. The company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.

# # #